载脂蛋白M降低与心力衰竭全谱不良结局相关
在PHFS研究部分参与者中检测载脂蛋白M(apo M),并在PHFS、华盛顿大学心衰注册研究和TOPCAT试验子集中验证其与结局的关系。结果显示循环apo M降低与死亡及死亡/心室辅助装置/心脏移植复合终点独立相关,且在射血分数降低和保留的心衰中均存在,并与炎症通路负相关。
要点
- 循环apo M降低与心衰患者死亡及不良复合终点独立相关
- 该关联在射血分数降低和保留的心衰中均存在,并在独立队列中重复验证
- apo M与炎症和凝血通路负相关,与LXR/RXR激活正相关
核心结论
- 循环apo M降低与人类心力衰竭全谱的不良结局独立相关。
研究设计与样本
- 在PHFS部分参与者(n=297)中用ELISA检测apo M,并用液相色谱-质谱法检测总S1P及分离HDL颗粒。
- 在PHFS(n=2170)及华盛顿大学心衰注册研究(n=173)和TOPCAT子集(n=218)中用修饰适配体法检测apo M验证其与结局的关系。
- 用SomaScan检测约5000种其他蛋白以识别与apo M相关的生物学通路。
主要发现
- 在PHFS中,apo M与死亡风险呈负相关(标准化HR 0.56,95%CI 0.51-0.61,P<0.0001)。
- 在PHFS中,apo M与死亡/心室辅助装置植入/心脏移植复合终点呈负相关(标准化HR 0.62,95%CI 0.58-0.67,P<0.0001)。
- 多变量校正后,apo M仍与死亡(HR 0.78,95%CI 0.69-0.88,P<0.0001)及死亡/心室辅助装置/心脏移植复合终点(HR 0.85,95%CI 0.76-0.94,P=0.001)相关。
- 分离HDL颗粒中S1P与apo M含量强相关(R=0.81,P<0.0001)。
- 与apo M最相关的典型通路包括炎症(负相关)、凝血系统(负相关)和LXR/RXR激活(正相关)。
临床怎么用
- 循环apo M降低可作为心衰患者不良结局的风险标志物,但尚不能用于指导治疗。
- apo M/S1P轴是否可作为心衰治疗靶点仍需进一步研究。
局限性
- 研究为观察性设计,不能确定apo M与结局的因果关系。
- 部分队列样本量有限,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apo (apolipoprotein) M mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P). Apo M exerts anti-inflammatory and cardioprotective effects in animal models. METHODS: In a subset of PHFS (Penn Heart Failure Study) participants (n=297), we measured apo M by Enzyme-Linked ImmunoSorbent Assay (ELISA). We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL particles to test the association between apo M and HDL-associated S1P. We confirmed the relationship between apo M and outcomes using modified aptamer-based apo M measurements among 2170 adults in the PHFS and 2 independent cohorts: the Washington University Heart Failure Registry (n=173) and a subset of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial; n=218). Last, we examined the relationship between apo M and ≈5000 other proteins (SomaScan assay) to identify biological pathways associated with apo M in heart failure. RESULTS: In the PHFS, apo M was inversely associated with the risk of death (standardized hazard ratio, 0.56 [95% CI, 0.51-0.61]; P<0.0001) and the composite of death/ventricular assist device implantation/heart transplantation (standardized hazard ratio, 0.62 [95% CI, 0.58-0.67]; P<0.0001). This relationship was independent of HDL cholesterol or apo AI levels. Apo M remained associated with death (hazard ratio, 0.78 [95% CI, 0.69-0.88]; P<0.0001) and the composite of death/ventricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-0.94]; P=0.001) in models that adjusted for multiple confounders. This association was present in both heart failure with reduced and preserved ejection fraction and was replicated in the Washington University cohort and a cohort with heart failure with preserved ejection fraction only (TOPCAT). The S1P and apo M content of isolated HDL particles strongly correlated (R=0.81, P<0.0001). The top canonical pathways associated with apo M were inflammation (negative association), the coagulation system (negative association), and liver X receptor/retinoid X receptor activation (positive association). The relationship with inflammation was validated with multiple inflammatory markers measured with independent assays. CONCLUSIONS: Reduced circulating apo M is independently associated with adverse outcomes across the spectrum of human heart failure. Further research is needed to assess whether the apo M/S1P axis is a suitable therapeutic target in heart failure.
引用
- Chirinos JA, Zhao L, Jia Y, et al. Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. Circulation. 2020. PMID: 32237898. doi:10.1161/CIRCULATIONAHA.119.045323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。